Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT

The extracted text presents a narrative review rather than a systematic review or meta‑analysis; no formal methods section, search strategy, database list, date range, or eligibility criteria are provided in the available extraction. As such, the paper synthesises historical, clinical, preclinical and medicinal chemistry literature selectively to address questions about routes/formulations, dosing effects, and endogenous DMT biology. Barker organises the material topically: (1) ayahuasca as a traditional source of DMT and its practical limitations for standardised therapeutics; (2) comparative pharmacology and effects of different routes (oral with MAOI, IV, IM, inhaled, insufflated, transdermal and others); (3) low‑dose and micro‑dose findings; (4) medicinal chemistry approaches to reduce MAO metabolism (for example deuteration and other side‑chain modifications); (5) in vitro and in vivo receptor and neuroplasticity data (including sigma‑1, 5‑HT receptors and downstream gene expression); and (6) evidence for endogenous synthesis and extracellular concentrations of DMT in animal and human tissues. Where experimental data are cited, dosing regimens, species, and key outcome measures are reported as presented in the source studies, but no unified quantitative synthesis method (meta‑analysis) is described in the extracted text.

Ayahuasca and formulation issues: Barker summarises ethnobotanical use of ayahuasca (Psychotria leaves + Banisteriopsis caapi harmala alkaloids) and reports that ayahuasca produces longer, milder subjective effects than injected DMT. Ayahuasca is described as relatively safe in acute studies and in long‑term consumers, but practical problems for clinical use include significant batch‑to‑batch variability of alkaloid content and degradation of harmala alkaloids under storage or heat, meaning tea component quantification before administration is necessary. The harmala MAOIs add their own pharmacology and complicate attribution of effects to DMT alone. Routes, doses and acute pharmacology: Oral DMT alone is inactive due to first‑pass MAO metabolism. Intramuscular (IM) DMT (0.2–1 mg/kg) typically has rapid onset (2–5 min) and lasts ~30–60 min, and is considered less intense than IV. Intravenous (IV) DMT studies in experienced users used 0.05–0.4 mg/kg doses, producing peak blood levels and subjective effects within ~2 min and negligible effects by 30 min; the lowest IV dose that produced statistically significant hallucinogenic effects was 0.2 mg/kg. IV administration produced dose‑dependent increases in blood pressure, heart rate, pupil diameter, rectal temperature, β‑endorphin, corticotropin and cortisol, with prolactin and growth hormone rising irrespective of dose. Vaporised/inhaled free‑base DMT is highly psychoactive with typical doses of 40–50 mg (larger reported), onset very rapid and effects usually lasting less than 30 min; however, inhalation/insufflation can be harsh and poorly tolerated. For ayahuasca, DMT doses of ~0.6–0.85 mg/kg produce effects that usually appear within 60 min, peak at 90 min and can last ~4 h (reflecting MAOI prolongation). The review cites that plasma concentrations in the range of 12–90 ng/ml are associated with hallucinogenic effects for exogenously administered DMT, but brain concentrations required for these effects remain unknown. Pharmahuasca and oral strategies: Combinations of DMT with harmala MAOIs (so‑called pharmahuasca) have been used to create a more standardisable oral formulation; typical reported ratios include 50 mg DMT:100 mg harmaline or combinations involving harmine and moclobemide (a reversible MAO‑A inhibitor). The drawback remains the system‑wide MAO inhibition and its off‑target effects. Low‑dose and micro‑dosing evidence: Barker notes growing anecdotal and limited experimental interest in micro‑dosing (commonly defined as ~5–10% of a typical hallucinogenic dose, given on schedule), though robust human evidence is scarce. Preclinical rat studies provide some signals: chronic intermittent low‑dose DMT (1 mg/kg IP every third day for ~2 months) produced an antidepressant‑like phenotype, enhanced fear‑extinction learning, and lacked anxiogenic effects seen with single high doses; one study reported that low‑dose intermittent DMT did not increase expression of several immediate‑early genes (egr1, egr2, arc, fos) or BDNF, and decreased dendritic spine density in females (p = 0.03) while prior work had shown spine density increases after a single high dose. Translational implications remain unclear and the author emphasises that animal low‑dose and human micro‑dose equivalence is not established. Medicinal chemistry approaches to oral activity: Two preclinical studies of deuterated DMT analogues (e.g. α,α,β,β‑d4‑DMT and related d4‑5MeO‑DMT) showed that deuteration at alpha positions reduced MAO metabolism, increasing brain concentrations 2–3‑fold at equivalent doses and prolonging detectability and behavioural effects after subcutaneous administration (doses reported: 2.5–10 mg/kg SC). Receptor binding experiments indicated little change in affinity from deuteration. Barker highlights these findings as a route to create an orally active, single‑molecule “deuterhuasca” that could avoid co‑administered MAOIs, though oral bioavailability data for these analogues are not reported in the extracted text. Other structural strategies (alpha‑substitutions, larger N‑alkyl groups, ring constraints) are discussed as methods to reduce MAO susceptibility or separate hallucinogenic from neuroplastic effects. In vitro and in vivo pharmacology: The review notes that while 5‑HT2A receptor binding is implicated in classic hallucinogenic subjective effects, DMT interacts with many targets beyond serotonin receptors, including 5‑HT2C, 5‑HT1A, glutamate receptors, dopamine, acetylcholine, trace amine‑associated receptors (TAARs), opioid receptors, and sigma‑1 receptors—the latter being the only known endogenous ligand agonist among these. Sigma‑1 receptor agonism by DMT is linked in studies to neuroprotection, enhancement of N‑methyl‑D‑aspartate receptor (NMDAR) function, anti‑inflammatory effects, reduced infarct size, improved functional recovery after transient focal brain ischemia in rats, protection against renal ischemia‑reperfusion injury, and regulation of cell survival/proliferation. DMT has also been shown to activate immediate‑early genes (c‑fos, egr‑1, egr‑2) associated with synaptic plasticity and to increase BDNF in some reports. Morales‑Garcia et al. reported modulation of adult neurogenesis by ayahuasca‑derived DMT in vitro and in vivo. Endogenous DMT evidence: Historical transmethylation hypotheses spurred discovery of the methylating enzyme indole‑N‑methyltransferase (INMT). INMT, together with aromatic amino acid decarboxylase (AADC), has been detected in peripheral tissues and, increasingly, within brain tissue of rodent, primate and human samples. Microdialysis studies in rats reported extracellular cortical DMT concentrations ranging from 0.05–1.8 nM (mean ~0.56 nM), with pinealectomy producing averaged levels ~1.02 nM; these values are in the same order of magnitude as extracellular 5‑HT (mean ~0.87 nM) and other monoamines. Importantly, DMT concentrations rose significantly after induced cardiac arrest (p = 0.00027 in pineal‑intact animals; p = 0.034 in pinealectomised animals). Co‑localisation of INMT and AADC in rat and human brain regions suggests local biosynthesis is possible. Barkersummary presents these findings as evidence that brain DMT exists at physiologically relevant concentrations and that biosynthesis may be inducible under specific physiological stressors.

Barker interprets the assembled evidence as indicating both promise and complexity in developing DMT‑based therapeutics. Multiple routes and formulations may each have appropriate uses—IV/IM and inhalation are suitable for controlled, acute exposures, while an orally active single‑molecule formulation would be preferable for routine or repeated dosing—but each route has trade‑offs. Co‑administration of MAOIs (as in ayahuasca or pharmahuasca) complicates mechanistic attribution and raises safety and standardisation challenges. Inhalation and insufflation methods are often unpleasant and variable, while parenteral routes require medical intervention. The author positions deuteration and other medicinal chemistry modifications as promising approaches to render DMT resistant to MAO metabolism, prolong action, lower required dose, and possibly permit oral administration without MAOI co‑treatment; preclinical data support increased brain exposure and preserved receptor binding for deuterated analogues, but oral bioavailability and human safety remain unreported in the extracted text. Barker also highlights the possibility of dissociating neuroplastic, potentially therapeutic effects from hallucinogenesis through structural modification—citing work that identifies a “psychoplastogenic pharmacophore” and non‑hallucinogenic analogues that retain plasticity‑promoting properties. Regarding endogenous DMT, the review stresses that measured extracellular DMT concentrations in rats are comparable to canonical neurotransmitters and increase under physiological stressors such as cardiac arrest, and that biosynthetic enzymes are present and co‑localised in brain tissue. Barker suggests that endogenous DMT could have homeostatic, neuroprotective or developmental roles mediated in part via sigma‑1 receptors, and that exogenous psychedelic treatments might interact with or modulate the same pathways. Key limitations acknowledged in the text include substantial variability and complexity in ayahuasca composition, sparse and heterogeneous data on human endogenous brain concentrations, limited translational data for micro‑ and low‑dose regimens, and a lack of molecular‑level understanding of how psychedelic interventions produce durable clinical effects. The author calls for further mechanistic and safety studies, standardisation of formulations for clinical research, and more work to characterise endogenous DMT synthesis, distribution and function so that therapeutic applications can be better targeted and understood.

Barker concludes that psychedelic therapy—of which DMT is a notable example—holds considerable therapeutic promise across multiple psychiatric and neurobiological domains, but that substantial gaps in foundational molecular and physiological knowledge remain. Multiple administration routes and formulations exist and may each find use, yet comparing results across ayahuasca, pharmahuasca and single‑molecule DMT studies will be difficult without greater standardisation. Deuterated or otherwise modified DMT analogues could offer a practical path to oral dosing without MAOI co‑administration and enable more consistent research and clinical use, but human data are lacking. Finally, because DMT is endogenous and interacts with sigma‑1, 5‑HT and other targets, clarifying its normal brain distribution and function is important both for understanding basic neurobiology and for refining psychedelic therapeutics; better mechanistic insight could reveal opportunities for lower‑dose, non‑hallucinogenic regimens as well as chemically modified therapeutics.